Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: October 28, 2009
Last updated: August 17, 2016
Last verified: August 2016

Panobinostat (LBH589) is a deacetylase inhibitor (DACi) which belongs to a structurally novel cinnamic hydroxamic acid class of compounds. It is one of the most potent class I/II pan-DAC inhibitor (pan-DACi) that has shown anti-tumor activity in pre-clinical models and patients with solid tumors and hematological malignancies.

To date, the pharmacokinetics (PK) of panobinostat has been characterized in patients with solid tumors and hematological malignancies participating in several phase I/II clinical studies. Panobinostat PK does not appear to be different in patients with solid tumors and hematological malignancies. However, the effect of organ dysfunction on PK of panobinostat is yet to be elucidated.

Kidney and liver are involved in the elimination and metabolism of panobinostat. The current study is designed to evaluate the impact of hepatic function status on panobinostat PK.

Condition Intervention Phase
Advanced Solid Tumors
Drug: LBH589
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Phase I, Open-label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Oral Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • To assess the effect of various degrees of impairment in hepatic function as measured by the National Cancer Institute-Cancer Therapy Evaluation Program (NCI-CTEP) criteria, on the pharmacokinetics of panobinostat. [ Time Frame: first 7 days ]

Secondary Outcome Measures:
  • To assess the effect of various degrees of impairment in hepatic function on the safety of panobinostat [ Time Frame: entire duration of study ]
  • To evaluate whether there is a relationship between panobinostat PK and safety parameters in patients with various degrees of hepatic organ function [ Time Frame: first 7 days ]
  • To explore anti-tumor activity associated with panobinostat. [ Time Frame: best overall response ]

Enrollment: 25
Study Start Date: March 2010
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HDACi Drug: LBH589


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient has documented diagnosis of advanced solid tumor for which no standard systemic therapy exists
  2. Patient has normal or abnormal hepatic organ function
  3. Patient has provided written informed consent prior to any screening procedures

Exclusion Criteria:

  1. Patient needing valproic acid for any medical condition during the study or within 5 days prior to the first panobinostat dose
  2. Patient received prior treatment with DAC inhibitors including panobinostat
  3. Patient requires treatment with warfarin that cannot be switched to another anticoagulant treatment prior to starting study drug
  4. Patient has encephalopathy
  5. Patient has ascites requiring intervention
  6. Female patient who is pregnant or breast feeding or with childbearing potential and not willing to use a double method of contraception up to 3 months after the end of study treatment. Male patient who is not willing to use a barrier method of contraception up to 3 months after the end of study treatment.

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01007968

United States, Utah
University of Utah / Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84103
Novartis Investigative Site
Leiden, Netherlands, 2300 RC
Novartis Investigative Site
Lund, Sweden, SE-221 85
Novartis Investigative Site
Stockholm, Sweden, SE-171 76
Novartis Investigative Site
St. Gallen, Switzerland, 9007
United Kingdom
Novartis Investigative Site
Edinburgh, United Kingdom, EH4 2XR
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals Identifier: NCT01007968     History of Changes
Other Study ID Numbers: CLBH589X2101
2009-012262-31 ( EudraCT Number )
Study First Received: October 28, 2009
Last Updated: August 17, 2016

Keywords provided by Novartis:
solid tumors
hepatic function

Additional relevant MeSH terms:
Antineoplastic Agents
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017